Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.59 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | EIF4E | P06730 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.35 |
| ▸ | EGFR | P00533 | 9/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 9/20 | 0.34 |
| ▸ | ERBB3 | P21860 | 9/20 | 0.34 |
| ▸ | ERBB4 | Q15303 | 9/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.32 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.32 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2078428 | 0.74 | DYRK1A (0.59) | DYRK1AIRAK4EIF4EMKNK1MKNK2 | |
| SCHEMBL3386908 | 0.74 | DYRK1A (0.59) | DYRK1AIRAK4EIF4EMKNK1MKNK2 | |
| SCHEMBL32425027 | 0.74 | DYRK1A (1.00) | DYRK1AIRAK4EIF4EMKNK1MKNK2 | |
| SCHEMBL397656 | 0.74 | DYRK1A (0.59) | DYRK1AIRAK4EIF4EMKNK1MKNK2 | |
| SCHEMBL13186164 | 0.74 | DYRK1A (0.59) | DYRK1AIRAK4EIF4EMKNK1MKNK2 | |
| SCHEMBL23158613 | 0.74 | DYRK1A (0.64) | DYRK1AIRAK4EIF4EMKNK1MKNK2 | |
| SCHEMBL29702869 | 0.74 | DYRK1A (0.59) | DYRK1AIRAK4EIF4EMKNK1MKNK2 | |
| SCHEMBL8223 | 0.74 | DYRK1A (1.00) | DYRK1AIRAK4EIF4EMKNK1MKNK2 | |
| SCHEMBL2760379 | 0.74 | DYRK1A (0.53) | DYRK1AIRAK4EIF4EMKNK1MKNK2 | |
| Hydrochloric Acid SCHEMBL3353317 | 0.72 | DYRK1A (0.57) | DYRK1AIRAK4EIF4EMKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227967-B2 | Inhibitor compounds of semicarbazide-sensitive amine oxidases | PROXIMAGEN LIMITED (GB) | 2016-01-05 | — | — | US | disclosed |
| US-9227967-B2 | Inhibitor compounds of semicarbazide-sensitive amine oxidases | PROXIMAGEN LIMITED (GB) | 2016-01-05 | — | — | US | disclosed |
| EP-2927233-A1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE | Proximagen Limited (GB) | 2015-10-07 | — | — | EP | disclosed |
| EP-2547677-B1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE | PROXIMAGEN LTD (GB) | 2015-05-06 | — | — | EP | disclosed |
| US-8853224-B2 | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | INDUSTRIAL RESEARCH LIMITED (NZ) | 2014-10-07 | — | — | US | disclosed |
| US-20130102587-A1 | New Enzyme Inhibitor Compounds | PROXIMAGEN LIMITED (GB) | 2013-04-25 | — | — | US | disclosed |
| US-20130102587-A1 | New Enzyme Inhibitor Compounds | PROXIMAGEN LIMITED (GB) | 2013-04-25 | — | — | US | disclosed |
| WO-2012150866-A1 | PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF | INDUSTRIAL RESEARCH LIMITED (NZ) | 2012-11-08 | — | — | WO | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20050026936-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| US-6803455-B2 | PYRROLO(3,2-D)PYRIMIDIN-7-YL)-1,4-IMINO-D-RIBITOL DERIVATIVES; FOR SUPPRESSION OF T-CELL FUNCTION | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY | 2004-10-12 | — | — | US | disclosed |
| US-20030096830-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | disclosed |
| US-6492347-B2 | TREATMENT AND/OR PROPHYLAXIS OF INFECTION CAUSED BY PROTOZOAN PARASITE BY ADMINISTERING COMPOUND TO INHIBIT PURINE NUCLEOSIDE HYDROLASE, PURINE NUCLEOSIDE PHOSPHORYLASE, AND/OR PURINE PHOSPHORIBOSYL TRANSFERASE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY | 2002-12-10 | — | — | US | disclosed |
| US-20020061898-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | disclosed |
| US-6228847-B1 | ADMINISTERING PYRROLO(3,2-D)PYRIMIDINE DERIVATIVES AS PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2001-05-08 | — | — | US | disclosed |
| CN-1279686-A | Inhibitors of nucleoside metabolism | ALBERT EINSTEIN COLLAGE OF MED (US) | 2001-01-10 | — | — | CN | disclosed |
| US-6066722-A | Inhibitors of nucleoside metabolism | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2000-05-23 | — | — | US | disclosed |
| US-5985848-A | EFFECTIVE INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE AND/OR NUCLEOSIDE HYDROLASES; TREATMENT AND/OR PROPHYLAXIS OF A PROTOZOAN INFECTION | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 1999-11-16 | — | — | US | disclosed |
| WO-1997049706-A1 | SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF | NOVARTIS AG (CH) | 1997-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026936-A1 | Inhibitors of nucleoside metabolism | CFH, CBR3, SLCO2B1 | DYRK1A 1535/4885IRAK4 4745/4885EIF4E 2646/4885 |
| US-20130102587-A1 | New Enzyme Inhibitor Compounds | SERPINB1, SSB, NFKBIA | DYRK1A 4354/4885IRAK4 3200/4885EIF4E 3726/4885 |
| US-20020061898-A1 | Inhibitors of nucleoside metabolism | PNP, APRT, NUDT14 | DYRK1A 2620/4885IRAK4 3113/4885EIF4E 2947/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | DYRK1A 3718/4885IRAK4 4670/4885EIF4E 3989/4885 |
| US-20030096830-A1 | Inhibitors of nucleoside metabolism | CFH, NADK, UGT1A3 | DYRK1A 1576/4885IRAK4 4423/4885EIF4E 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.